Buy Mounjaro 2.5mg KwikPen Injection Online / Tirzepatide 2.5mg Injection Online

MOUNJARO 2 5MG KWIKPEN

Name: MOUNJARO 2 5MG KWIKPEN
Brand: LILLY PRODUCTS
SKU: 95064
Price: 11812.50 INR
Availability: InStock

Item requires a valid prescription

Manufactured By LILLY PRODUCTS

Composition TIRZEPATIDE 2 5MG

RS 11812.50

MRP RS 13125.00

(10% OFF)

Includes all taxes

Package SIZE

( 2.4ML )

100% Authentic
Products

Free
Shipping*

Products
Return Policy

Information about MOUNJARO 2 5MG KWIKPEN

Description:

Mounjaro 2 5mg KwikPen Tirzepatide 2 5mg is a first in class dual GIP glucose dependent insulinotropic polypeptide and GLP 1 glucagon like peptide 1 receptor agonist manufactured by Eli Lilly and Company indicated for the management of Type 2 Diabetes Mellitus in adults as an adjunct to diet and exercise and for chronic weight management in adults with obesity or overweight with at least one weight related comorbidity The 2 5mg KwikPen is the initiation dose designed to improve tolerability during the first four weeks of therapy Available from Shabbir Medical Hall at the best price in India this genuine Eli Lilly prescription injection pen is available online with cold chain compliant home delivery BENEFITS Mounjaro 39 s dual receptor mechanism delivers clinically superior outcomes compared to single receptor GLP 1 agonists By simultaneously activating GIP and GLP 1 receptors Tirzepatide enhances glucose stimulated insulin secretion suppresses glucagon slows gastric emptying and powerfully reduces appetite and caloric intake Clinical trials SURPASS programme demonstrated HbA1c reductions of up to 2 58 and body weight reductions of up to 22 5 at higher maintenance doses making it one of the most efficacious agents available for both diabetes and obesity The once weekly KwikPen format improves adherence and convenience USAGE OVERVIEW Mounjaro 2 5mg is administered as a once weekly subcutaneous injection into the abdomen thigh or upper arm The 2 5mg starting dose is maintained for 4 weeks before dose escalation under physician guidance It can be taken at any time of day with or without food SAFETY OVERVIEW The most common side effects are gastrointestinal nausea vomiting diarrhoea and constipation typically occurring during initial dose escalation and resolving over time Serious considerations include thyroid C cell tumour risk contraindicated in MTC MEN2 history pancreatitis and hypoglycaemia risk when combined with insulin or sulphonylureas Not returnable once delivered due to cold chain temperature sensitivity

Uses / Indications:

PRIMARY USES Type 2 Diabetes Mellitus T2DM as an adjunct to diet and exercise to improve glycaemic control in adults reduces HbA1c significantly as monotherapy or add on therapy Chronic Weight Management in adults with BMI 30 kg m obesity or BMI 27 kg m with at least one weight related comorbidity hypertension dyslipidaemia obstructive sleep apnoea cardiovascular disease ADDITIONAL OFF LABEL EMERGING USES Cardiovascular risk reduction ongoing data from SURPASS CVOT and SELECT trial derivatives show benefit in reducing MACE events Non alcoholic steatohepatitis NASH MASLD emerging evidence for hepatic fat reduction Polycystic Ovary Syndrome PCOS with insulin resistance and obesity under specialist supervision Pre diabetes metabolic syndrome with obesity physician directed only NOTE Mounjaro is NOT indicated for Type 1 Diabetes Mellitus Diabetic ketoacidosis Patients with personal or family history of Medullary Thyroid Carcinoma MTC or Multiple Endocrine Neoplasia syndrome type 2 MEN 2

Interactions / Warnings:

THYROID TUMOUR WARNING BLACK BOX CONTRAINDICATION In rodent studies Tirzepatide caused dose dependent thyroid C cell tumours including medullary thyroid carcinoma Mounjaro is CONTRAINDICATED in patients with a personal or family history of Medullary Thyroid Carcinoma MTC or Multiple Endocrine Neoplasia syndrome type 2 MEN 2 Report any neck lump dysphagia hoarseness or difficulty breathing immediately PANCREATITIS Acute pancreatitis including fatal cases has been reported with GLP 1 receptor agonists Discontinue Mounjaro immediately if pancreatitis is suspected severe abdominal pain Do NOT reinstate Mounjaro if pancreatitis is confirmed DIABETIC RETINOPATHY Rapid improvement in glycaemic control has been associated with temporary worsening of diabetic retinopathy Monitor patients with pre existing retinopathy closely RENAL IMPAIRMENT No dose adjustment required for mild moderate impairment Severe dehydration from GI side effects can worsen renal function ensure adequate hydration HYPOGLYCAEMIA RISK Mounjaro as monotherapy has low hypoglycaemia risk glucose dependent mechanism Risk increases significantly when combined with insulin or sulphonylureas proactive dose reduction of these agents should be discussed with your physician GALLBLADDER DISEASE Rapid weight loss with Mounjaro may increase the risk of gallstone formation cholelithiasis and gallbladder disease Report right upper abdominal pain fever or jaundice promptly DRIVING MACHINERY Dizziness may occur particularly in patients on combination therapy with risk of hypoglycaemia Assess personal response before driving ELDERLY USE 65 years No overall difference in efficacy but greater attention to hydration renal function and hypoglycaemia risk Dose escalation should be cautious PAEDIATRIC USE Safety and efficacy in children 18 years not established Not recommended

Pregnancy interaction:

PREGNANCY SAFETY Tirzepatide is NOT recommended during pregnancy Animal reproductive studies showed foetal harm at clinically relevant doses Women of childbearing potential should use effective contraception during treatment Due to the long half life of Tirzepatide 5 days with effects lasting weeks contraception should be continued for at least 1 month after stopping Mounjaro many guidelines recommend 2 months If pregnancy is confirmed during treatment discontinue Mounjaro immediately and consult your endocrinologist and obstetrician Uncontrolled blood sugar during pregnancy poses significant risks to both mother and baby transition to appropriate diabetes management e g insulin under specialist guidance BREASTFEEDING It is not known whether Tirzepatide passes into human breast milk Breastfeeding is NOT recommended during treatment due to potential risk to the nursing infant Discuss with your doctor the benefits and risks before deciding on breastfeeding versus continuing Mounjaro FERTILITY No specific data on Tirzepatide and human fertility Significant weight loss common with Mounjaro can affect reproductive hormones inform your gynaecologist endocrinologist DOCTOR CONSULTATION WARNING Never stop Mounjaro without consulting your physician particularly if used for blood sugar control abrupt discontinuation may cause glycaemic deterioration

Expert advice:

PHARMACIST BEST PRACTICES 1 DOSE ESCALATION IS NON NEGOTIABLE DO NOT SKIP STEPS The 2 5mg starting dose is designed exclusively for tolerability initiation it is NOT a therapeutic dose Never skip the 4 week step up schedule Rapid escalation dramatically increases GI side effects nausea vomiting diarrhoea and risks treatment abandonment Each dose step must be maintained for at least 4 weeks before any upward adjustment 2 MANAGE GI SIDE EFFECTS PROACTIVELY GI side effects peak during the first 4 8 weeks of treatment and usually improve significantly with time Advise patients to eat smaller meals avoid high fat or spicy foods eat slowly stay upright after eating and remain well hydrated Anti emetics ondansetron metoclopramide may be used short term under physician advice if nausea is severe 3 BLOOD GLUCOSE MONITORING IS ESSENTIAL Patients on insulin or sulphonylureas must increase blood glucose monitoring frequency particularly after each dose escalation Proactive dose reduction of insulin sulphonylurea is commonly needed do not wait for hypoglycaemic episodes before acting 4 STRICT COLD CHAIN COMPLIANCE Mounjaro is a temperature sensitive biological product Always refrigerate at 2 C 8 C immediately upon receipt If kept at room temperature use within 21 days and do NOT return to refrigerator Never expose to temperatures above 30 C or direct sunlight Use an insulated cool bag when transporting Inspect the pen solution before each dose 5 PREGNANCY CONTRACEPTION COUNSELLING Women of reproductive age must be counselled that Mounjaro is not safe in pregnancy and that oral contraceptive absorption may be temporarily impaired during dose escalation Recommend back up contraception condoms IUD for 4 weeks after each dose increase Continue contraception for at least 1 month after stopping Mounjaro MONITORING ADVICE HbA1c Check at 3 months after initiation and every 3 6 months during maintenance to assess glycaemic response Fasting blood glucose and self monitoring SMBG Increased frequency when on concomitant insulin sulphonylureas Body weight Monthly measurement document total body weight loss trajectory Renal function eGFR creatinine Baseline and if persistent vomiting diarrhoea causes dehydration concern Thyroid monitoring Not routinely required but examine neck at each visit report any new thyroid symptoms promptly Gallbladder Abdominal ultrasound if symptomatic biliary disease suspected Lipid profile 3 6 months after starting Mounjaro typically improves lipid parameters COMPLIANCE TIPS Set a recurring weekly reminder same day and time each week for injection Keep a dose log on the pen itself mark each of the 4 doses used Store pen in its original carton in the refrigerator door shelf for easy access Carry your physician s prescription and a diabetes obesity medication alert card Order next pen 1 week before current pen runs out to maintain uninterrupted therapy Note Product is NOT returnable once delivered order only confirmed quantities SAFETY TIPS Inspect pen before each use clear slightly yellow solution only discard if cloudy discoloured or expired Never share a KwikPen even with a new needle sharing poses cross contamination risk Rotate injection sites weekly to prevent skin nodule formation lipodystrophy Dispose of used needles in a puncture resistant sharps container Carry fast acting glucose glucose tablets juice if on concomitant insulin sulphonylureas Inform all treating doctors dentists and emergency personnel that you are on Tirzepatide

Side Effects:

COMMON SIDE EFFECTS 1 in 10 people mainly GI during dose initiation escalation Nausea most common typically mild moderate transient Vomiting Diarrhoea Constipation Decreased appetite and reduced food intake Abdominal pain bloating indigestion dyspepsia Injection site reactions redness bruising itching nodule formation Belching flatulence Fatigue and asthenia especially early in treatment SERIOUS SIDE EFFECTS contact your doctor immediately Pancreatitis severe persistent upper abdominal pain may radiate to back vomiting discontinue and seek urgent medical review Hypoglycaemia particularly when combined with insulin or sulphonylureas sweating tremor rapid heartbeat confusion Acute gallbladder disease cholelithiasis gallstones cholecystitis right upper abdominal pain fever jaundice Heart rate increase persistent tachycardia has been reported Acute kidney injury secondary to dehydration from vomiting diarrhoea reduced urine output ankle swelling Severe allergic reactions anaphylaxis urticaria angioedema bronchospasm collapse EMERGENCY SIGNS SEEK IMMEDIATE MEDICAL HELP Severe persistent abdominal pain pancreatitis Neck lump difficulty swallowing hoarseness possible thyroid tumour Swelling of face lips tongue or throat difficulty breathing anaphylaxis Signs of severe low blood sugar confusion seizures unconsciousness

How to use:

DOSAGE GUIDANCE always as directed by your endocrinologist or physician STARTING DOSE 2 5mg subcutaneously ONCE WEEKLY for 4 weeks Purpose tolerability initiation the 2 5mg dose is not a therapeutic maintenance dose DOSE ESCALATION under physician guidance After Week 4 increase to 5mg once weekly If needed further escalation in 2 5mg increments every 4 weeks Available strengths 2 5mg 5mg 7 5mg 10mg 12 5mg 15mg Maximum approved dose 15mg once weekly MISSED DOSE If 4 days since missed dose administer as soon as possible then resume weekly schedule If 4 days since missed dose skip the missed dose and continue with next scheduled dose Do not administer two doses within 3 days of each other HOW TO INJECT Route Subcutaneous injection only abdomen avoiding 5 cm around navel front outer thigh or upper outer arm Rotate injection sites weekly to prevent lipodystrophy Can be injected at any time of day with or without food KwikPen delivers 4 doses one per week keep track of doses used INJECTION TECHNIQUE 1 Wash hands thoroughly 2 Remove pen cap check solution should be clear to slightly yellow do not use if cloudy discoloured or with particles 3 Select injection site and clean skin with alcohol swab 4 Pinch skin insert needle fully press and hold button until dose counter returns to 0 5 Count to 5 before removing needle to ensure full dose delivery 6 Replace needle cap dispose in sharps container STORAGE Refrigerate at 2 C 8 C in original carton Do NOT freeze Once at room temperature 30 C use within 21 days do NOT return to refrigerator Protect from light and heat Keep out of reach of children NOT returnable once delivered temperature sensitive cold chain product

How it works:

Mechanism of Action Mounjaro contains Tirzepatide a novel synthetic peptide that is the first approved dual GIP GLP 1 receptor agonist a mechanism class not previously available in any other diabetes or obesity medication DUAL RECEPTOR ACTIVATION 1 GIP RECEPTOR GIPR AGONISM GIP glucose dependent insulinotropic polypeptide is an incretin hormone released from intestinal K cells after meals Tirzepatide s GIP agonism enhances meal stimulated insulin secretion improves insulin sensitivity in adipose tissue and contributes to weight loss via central appetite suppression GIP receptor activation also reduces nausea making Tirzepatide better tolerated than GLP 1 only agents 2 GLP 1 RECEPTOR GLP 1R AGONISM GLP 1 glucagon like peptide 1 is released from intestinal L cells post meal Tirzepatide s GLP 1 agonism suppresses glucagon secretion slows gastric emptying reduces post meal glucose spikes signals the hypothalamus to reduce appetite and increase satiety Results in significantly reduced caloric intake and prolonged fullness NET CLINICAL EFFECTS Glucose dependent insulin release low hypoglycaemia risk as monotherapy HbA1c reduction of 1 87 2 58 SURPASS programme Body weight reduction of 15 22 5 at maintenance doses SURMOUNT programme Reduction in systolic blood pressure and improvement in lipid profile Superior efficacy vs semaglutide GLP 1 only demonstrated in SURPASS 2 trial

Faq for medicine:

1 What is Mounjaro 2 5mg KwikPen and who is it prescribed for Mounjaro 2 5mg KwikPen contains Tirzepatide 2 5mg a first in class dual GIP and GLP 1 receptor agonist manufactured by Eli Lilly It is prescribed for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycaemic control Mounjaro 2 5mg is the initiating dose designed to minimize gastrointestinal side effects while establishing treatment tolerance before dose escalation 2 How is the Mounjaro 2 5mg KwikPen administered correctly Mounjaro 2 5mg KwikPen is administered as a once weekly subcutaneous injection in the abdomen thigh or upper arm The injection site should be rotated each week The KwikPen is a prefilled single dose device that delivers a precise 0 5ml injection It can be administered at any time of day with or without meals Patients should follow the device instructions and healthcare provider guidance for proper administration technique 3 What makes Mounjaro 2 5mg different from GLP 1 agonists like semaglutide Mounjaro 2 5mg KwikPen Tirzepatide uniquely activates both GIP and GLP 1 receptors unlike semaglutide which targets only GLP 1 receptors This dual mechanism provides enhanced insulin secretion suppressed glucagon slowed gastric emptying and stronger appetite reduction Clinical trials show Tirzepatide achieves superior HbA1c reduction and weight loss compared to semaglutide making Mounjaro a differentiated next generation diabetes therapy 4 What are the expected side effects of Mounjaro 2 5mg KwikPen during initiation Common side effects of Mounjaro 2 5mg KwikPen include nausea diarrhea vomiting constipation and decreased appetite which are most pronounced during the initial weeks These gastrointestinal effects typically diminish as the body adapts The 2 5mg starting dose is specifically designed to reduce tolerability issues Patients should inform their physician if side effects are severe or persistent during early Mounjaro therapy 5 Can Mounjaro 2 5mg KwikPen be used in patients with cardiovascular disease Mounjaro 2 5mg KwikPen Tirzepatide has demonstrated non inferior cardiovascular safety in type 2 diabetes patients in the SURPASS CVOT trial Early data suggest potential cardiovascular benefits Mounjaro is used in patients with type 2 diabetes who may have cardiovascular risk factors However it is currently approved for glycaemic and weight management and its cardiovascular benefit profile continues to be studied in ongoing trials 6 How soon should patients expect to escalate from Mounjaro 2 5mg to higher doses Patients typically remain on Mounjaro 2 5mg KwikPen for 4 weeks to establish tolerability before escalating to 5mg Subsequent dose escalations 7 5mg 10mg 12 5mg up to 15mg occur every 4 weeks as tolerated This gradual titration schedule minimizes gastrointestinal side effects The target maintenance dose providing optimal glycaemic and weight management outcomes for most patients is between 10mg and 15mg weekly

Medicine interaction:

DRUG INTERACTIONS Insulin Insulin Secretagogues Sulphonylureas Glinides Significantly increased risk of hypoglycaemia Dose reduction of insulin or sulphonylurea is often required when initiating Tirzepatide Monitor blood glucose closely Oral Contraceptives Tirzepatide slows gastric emptying may transiently reduce absorption of oral medications including oral contraceptives Consider non oral contraception or use back up contraception for 4 weeks after each dose escalation Warfarin Oral Anticoagulants Slowed gastric emptying may alter anticoagulant absorption Monitor INR more frequently when initiating or adjusting Mounjaro Other GLP 1 Receptor Agonists e g Semaglutide Liraglutide Dulaglutide Do NOT combine additive GI side effects and increased hypoglycaemia risk Not recommended concurrently Thyroid Medications No direct pharmacokinetic interaction documented but Tirzepatide may affect thyroid C cells see Warnings Metformin Generally safe to combine no clinically significant pharmacokinetic interaction Commonly used as combination therapy for T2DM VACCINE INTERACTIONS No clinically significant interactions with vaccines documented SUPPLEMENT INTERACTIONS No major interactions Always inform your doctor of all supplements vitamins and herbal products you take